ArticleNeurochemical research2026
Electroacupuncture Promotes Synaptic Recovery After Cerebral Ischemia-Reperfusion by Activating SIRT1 to Inhibit the NF-κB Pathway and Regulate Astrocyte Phenotypic Transformation.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Functional recovery after cerebral ischemia-reperfusion injury (CIRI) depends on synaptic plasticity, which is profoundly modulated by astrocyte phenotypes-the neurotoxic A1 phenotype exacerbates damage, while the A2 phenotype supports repair. Electroacupuncture (EA) is neuroprotective, yet whether it promotes synaptic repair by orchestrating this phenotypic switch remains elusive. We hypothesized that EA drives this switch via the SIRT1-NF-κB axis to enhance synaptic recovery. Mice that underwent middle cerebral artery occlusion/reperfusion (MCAO/R) were randomly assigned to the following experimental groups: MCAO/R, EA, EA + SIRT1 inhibitor (Selisistat), or MCAO/R + NF-κB inhibitor (PDTC). Sham-operated mice served as Sham group. EA at GV20 and GV16 was applied daily for 7 days. Neurological function, cerebral blood flow, SIRT1 activity, NF-κB pathway, astrocyte markers (C3, S100A10), inflammatory cytokines, and synaptic proteins were assessed using behavioral tests, imaging, Western blotting, immunofluorescence, ELISA, and transmission electron microscopy. EA significantly improved neurological function and cerebral blood flow. Notably, EA upregulated both the protein level and deacetylase activity of SIRT1 while concurrently suppressing NF-κB phosphorylation, indicating a shift toward anti-inflammatory signaling. This molecular change was accompanied by a significant reduction in the A1 astrocytic marker C3 and pro-inflammatory cytokines, alongside a pronounced increase in the A2 marker S100A10 and anti-inflammatory mediators. Furthermore, EA restored synaptic protein expression and preserved synaptic ultrastructural integrity. The SIRT1 inhibitor Selisistat reversed all these beneficial effects, whereas the NF-κB inhibitor PDTC phenocopied EA‑induced astrocyte phenotype modulation. EA drives astrocyte phenotypic switching from A1 to A2 via the SIRT1-NF-κB axis, reshaping the inflammatory microenvironment to promote synaptic repair and functional recovery after CIRI.
Indexed as
Identifiers
42149357What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.